Cibmtr
Business Services · Minnesota, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
500 N 5th St, Minneapolis, Minnesota, 55...Phone Number
(414) 805-0700Website
www.cibmtr.orgRevenue
$8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cibmtr
CIBMTR is a research collaboration focused on improving outcomes in cellular therapy through transformative and collaborative research. They lead observational and prospective studies in hematopoietic cell transplantation and provide comprehensive data management for both recipients and donors. Their primary intended clients are researchers, clinicians, and centers involved in cellular therapies, providing them with resources, training, and membership opportunities. With an extensive database and numerous publications, CIBMTR aims to enhance the quality of life and survival rates for patients receiving cellular therapies.Explore more
Cibmtr Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cibmtr your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Cibmtr, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Cibmtr recently announced quarterly report
Check out if Cibmtr is spiking on competitors!
Product Launch: Get notified when Cibmtr launches new products
Funding: Get notified immidiatlly once Cibmtr has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Cibmtr has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Cibmtr
Click to see if Cibmtr had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Cibmtr
Find more new buyers
Compare Similar Companies to Cibmtr
Compare insights from companies similar to Cibmtr, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cibmtr is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cibmtr is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cibmtr.
Cibmtr Tech Stack
A closer look at the technologies used by Cibmtr
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Cibmtr News & Media
New NMDP-Sponsored Trial Data Show Comparable Patient-Reported Outcomes and Survival Across Levels of Genetic Mismatch
ACCESS trial results at the 2026 Tandem Meetings reinforce mismatched unrelated donors as safe, effective and well-tolerated optionExicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster at the upcoming 2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), taking place February 4-7, 2026, in Salt Lake CMesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies in adults with severe acute graft versus host disease (aGvHD) who fail corticosteroids, and the high mortality in these patients, Mesoblast and the United States National Institutes of Health (NIH)-funded Blood and Marrow Transplant Clinical Trials Network (BMT CTBeam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in an oral presentation at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blo
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Cibmtr
Sign Up For FreeTo access detailed company insights
CIBMTR is a research collaboration focused on improving outcomes in cellular therapy through transformative and collaborative research. They lead observational and prospective studies in hematopoietic cell transplantation and provide comprehensive data management for both recipients and donors. Their primary intended clients are researchers, clinic... Read More
